• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

FDA Puts New Limits on Oral MS Drug


Reacting to a death associated with the multiple sclerosis drug fingolimod (Gilenya), the FDA said patients with certain cardiac risk factors should not take the oral agent.

The death was reported last year and the agency had promised to investigate it.

In an announcement on Monday, the FDA said it still didn't know whether fingolimod caused the patient's death, but nevertheless it was adding new contraindications to the drug's label, as well as a beefed-up recommendation for monitoring patients after dosing.

Read the full story: http://hcp.lv/Md4ptW

Source: MedPage Today

Related Videos
Related Content
© 2023 MJH Life Sciences
All rights reserved.